A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
The main purpose of this study is to compare the overall survival (OS) of nivolumab plus ipilimumab versus standard of care (SOC) (sorafenib or lenvatinib) in all randomized participants with advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
Hepatocellular Carcinoma
DRUG: Nivolumab|DRUG: Ipilimumab|DRUG: Sorafenib|DRUG: lenvatinib
Overall Survival (OS), Up to 4 years
Objective Response Rate (ORR), Up to 4 years|Duration of Response (DOR), Up to 4 years|Time to Symptom Deterioration (TTSD), Up to 4 years
The main purpose of this study is to compare the overall survival (OS) of nivolumab plus ipilimumab versus standard of care (SOC) (sorafenib or lenvatinib) in all randomized participants with advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy.